M&A | Partnerships

Bone Therapeutics granted an exclusive license to develop and collaborate on ALLOB in Greater China and a number of other major Asian countries.

Eisai and Seikagaku will co-develop and market the SI-613 sodium hyaluronate therapeutic agent in South Korea for the treatment of knee osteoarthritis.

Fibrinet enables safe and rapid preparation of Platelet-Rich Fibrin Membrane and Platelet-Rich Fibrin Gel from a small sample of blood at the point of care.

LifeHealthcare will sell STIMULAN and genex calcium matrices for surgical use in musculoskeletal infections, trauma, spine and foot/ankle.

The technology has shown encouraging early results for regrowth of long bone defects in patients who have lost more than six centimeters of bone.

The companies have collaborated since 2015 to develop collagen-based bone graft products used in orthopedic and dental applications.

DUROLANE single-injection hyaluronic acid treats pain associated with osteoarthritis in the knee, hip and small joints.

Seikagaku and Eisai will co-develop and market knee osteoarthritis treatment SI-613 in China.

Acumed entered into an agreement to distribute Vivorte's orthobiologic portfolio on an exclusive basis.

Biologics4Life completed an exclusive licensing agreement to secure rights to initial technologies for bone tissue regeneration.